CN104507964B - P2x7受体拮抗剂和激动剂 - Google Patents

P2x7受体拮抗剂和激动剂 Download PDF

Info

Publication number
CN104507964B
CN104507964B CN201380040371.6A CN201380040371A CN104507964B CN 104507964 B CN104507964 B CN 104507964B CN 201380040371 A CN201380040371 A CN 201380040371A CN 104507964 B CN104507964 B CN 104507964B
Authority
CN
China
Prior art keywords
amino acid
seq
single variable
polypeptide
immunoglobulin single
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380040371.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN104507964A (zh
Inventor
韦尔贝克·奥乌苏丹夸
弗里德里希·诺尔特
卡特林恩·斯托特勒斯
图恩·莱瑞曼斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hamburg Eppendorf University Medical Center
Ablynx NV
Original Assignee
Ablynx NV
Universitatsklinikum Hamburg Eppendorf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ablynx NV, Universitatsklinikum Hamburg Eppendorf filed Critical Ablynx NV
Publication of CN104507964A publication Critical patent/CN104507964A/zh
Application granted granted Critical
Publication of CN104507964B publication Critical patent/CN104507964B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201380040371.6A 2012-06-01 2013-05-31 P2x7受体拮抗剂和激动剂 Active CN104507964B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261654417P 2012-06-01 2012-06-01
US61/654,417 2012-06-01
PCT/EP2013/061257 WO2013178783A1 (en) 2012-06-01 2013-05-31 P2x7 receptor antagonists and agonists

Publications (2)

Publication Number Publication Date
CN104507964A CN104507964A (zh) 2015-04-08
CN104507964B true CN104507964B (zh) 2020-05-15

Family

ID=48579032

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380040371.6A Active CN104507964B (zh) 2012-06-01 2013-05-31 P2x7受体拮抗剂和激动剂

Country Status (6)

Country Link
US (2) US9908935B2 (enExample)
EP (1) EP2855518A1 (enExample)
JP (2) JP6608698B2 (enExample)
CN (1) CN104507964B (enExample)
AU (2) AU2013269606B2 (enExample)
WO (1) WO2013178783A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2747644C (en) * 2008-12-19 2023-01-24 Ablynx N.V. Method for generation of immunoglobulin sequences
WO2013178783A1 (en) 2012-06-01 2013-12-05 Ablynx N.V. P2x7 receptor antagonists and agonists
WO2014182601A1 (en) * 2013-05-08 2014-11-13 Children's Medical Center Corporation A method of preventing and treating type 1 diabetes, allograft rejection and lung fibrosis (by targeting the atp/p2x7r axis)
IL295534B2 (en) 2014-05-16 2025-03-01 Ablynx Nv Improved immunoglobulin variable sites
IL318433A (en) 2014-05-16 2025-03-01 Ablynx Nv Improved immunoglobulin variable complexes
WO2016154683A1 (en) * 2015-04-02 2016-10-06 Biosceptre (Uk) Limited Pain treatment
US10875918B2 (en) 2015-11-12 2020-12-29 Ablynx N.V. P2X7 receptor binders and polypeptides comprising the same
PL233352B1 (pl) * 2016-09-15 2019-10-31 Adamed Spolka Z Ograniczona Odpowiedzialnoscia Przeciwnowotworowe białko fuzyjne
CN109321589A (zh) * 2018-10-15 2019-02-12 潍坊医学院 一种制备p2x7r免疫原的方法
CN110054691B (zh) * 2019-05-09 2021-09-07 潍坊医学院 一种抗人p2rx7单克隆抗体的杂交瘤细胞系
US12448440B2 (en) * 2019-08-23 2025-10-21 Loyota University Of Chicago Compositions comprising antibodies or antibody fragments which bind the P2X4 receptor
CA3198258A1 (en) 2020-11-30 2022-06-02 Yosuke Imai Medicine for alleviating neuropathic pain
US20240415974A1 (en) 2022-12-23 2024-12-19 Ablynx N.V. Protein-based conjugation carriers
AR131869A1 (es) 2023-02-17 2025-05-07 Ablynx Nv POLIPÉPTIDOS QUE SE UNEN AL RECEPTOR DE Fc NEONATAL

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004090097A2 (en) * 2003-04-03 2004-10-21 Bristol-Myers Squibb Company Polynucleotide encoding a novel human p2x7 splice variant, hbmyp2x7v
CN102257003A (zh) * 2008-12-19 2011-11-23 埃博灵克斯股份有限公司 用于产生针对细胞相关抗原如p2x7、cxcr7或cxcr4的免疫球蛋白的基因免疫

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8124730B1 (en) 2004-04-02 2012-02-28 Bristol-Myers Squibb Company Polynucleotide encoding a novel human P2X7 splice variant, HBMYP2X7v
WO2013178783A1 (en) 2012-06-01 2013-12-05 Ablynx N.V. P2x7 receptor antagonists and agonists

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004090097A2 (en) * 2003-04-03 2004-10-21 Bristol-Myers Squibb Company Polynucleotide encoding a novel human p2x7 splice variant, hbmyp2x7v
CN102257003A (zh) * 2008-12-19 2011-11-23 埃博灵克斯股份有限公司 用于产生针对细胞相关抗原如p2x7、cxcr7或cxcr4的免疫球蛋白的基因免疫

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
P2X7受体短肽单克隆抗体的制备及鉴定;谭超;《生物技术通报》;20121231(第12期);167-172 *
P2z /P2x7受体检测的研究;彭黎明;《四 川 大 学 学 报 ( 医 学 版 )》;20030131;第34卷(第1期);148-150 *

Also Published As

Publication number Publication date
AU2013269606A1 (en) 2014-12-18
US9908935B2 (en) 2018-03-06
US20180244769A1 (en) 2018-08-30
AU2018217239A1 (en) 2018-08-30
JP2018162269A (ja) 2018-10-18
AU2018217239B2 (en) 2020-07-30
US10544216B2 (en) 2020-01-28
AU2013269606B2 (en) 2018-05-17
US20150133637A1 (en) 2015-05-14
EP2855518A1 (en) 2015-04-08
CN104507964A (zh) 2015-04-08
JP6608698B2 (ja) 2019-11-27
CA2875234A1 (en) 2013-12-05
WO2013178783A1 (en) 2013-12-05
JP2015525211A (ja) 2015-09-03
JP6681433B2 (ja) 2020-04-15

Similar Documents

Publication Publication Date Title
CN104507964B (zh) P2x7受体拮抗剂和激动剂
US11384151B2 (en) CX3CR1-binding polypeptides comprising immunoglobulin single variable domains
JP2023002706A (ja) 抗ｐｄｌ１抗体、活性化可能抗ｐｄｌ１抗体、およびその使用方法
EP3157955B1 (en) Kv1.3 binding immunoglobulins
JP2013519364A (ja) アゴニストｄｒ５結合ポリペプチド
KR20110119806A (ko) 개선된 항­ｔｎｆｒ1 폴리펩티드，항체 가변 도메인 및 길항제
TW201132353A (en) WISE binding agents and epitopes
TW202241947A (zh) 包含靶向磷脂醯肌醇蛋白聚糖—３和ｔ細胞受體的免疫球蛋白單可變結構域的多肽
JP2024509766A (ja) Ｐｄ－ｌ１及びｃｄ４７に対する二重特異性単一ドメイン抗体及びその用途
AU2016352695B2 (en) Improved P2X7 receptor binders and polypeptides comprising the same
JP2024512633A (ja) 抗ｓｅｍａ３ａ抗体およびその用途
JP2024512252A (ja) Ｃｄ４７に対する単一ドメイン抗体及びその用途
CA2875234C (en) P2x7 receptor antagonists and agonists
HK40077734A (en) Cx3cr1-binding polypeptides
HK1205154B (en) Cx3cr1-binding polypeptides

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20151021

Address after: Belgium root taetz wynad

Applicant after: Ablynx NV

Applicant after: The Hamburg Eppendorf University Medical Center

Address before: Belgium root taetz wynad

Applicant before: Ablynx NV

GR01 Patent grant
GR01 Patent grant